Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi).

Stefano DuranteFrancesco CucciaMichele RigoGiovanni CaminitiFederico MastroleoRoberta LazzariGiulia CorraoGiuseppe CarusoSabrina VigoritoFederica CattaniGiuseppe FerreraVito ChianteraFilippo AlongiNicoletta ColomboBarbara Alicja Jereczek-Fossa

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)

Stereotactic body radiotherapy combined with PARPi continuation may be an effective and safe strategy for managing ovarian cancer patients with oligoprogression on PARPi maintenance therapy. Prospective research is warranted to shed more light on this approach.

Keyphrases

early stage
locally advanced
radiation induced
radiation therapy
squamous cell carcinoma
brain metastases
structural basis